To include your compound in the COVID-19 Resource Center, submit it here.

Celator, Jazz Pharmaceuticals deal

Jazz will acquire cancer company Celator for $30.25 per share in cash,

Read the full 127 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE